ClinicalTrials.gg
CompletedNCT01194882Updated Feb 15, 2018

Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes

A Phase 3 interventional study of HUMAN INSULIN (BIOSYNTHETIC) and Insuplant in Diabetes Mellitus, Type 1, sponsored by Sanofi. Completed at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-15.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
479
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
4th of 35
479 · median 74
Started
2010
the only one that year
Phase 3
17 of 35
none open now
Registered
23rd of 35
by date
Lead sponsor
1 of 35
Sanofi

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 17 in phase 3, and was the 23rd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Primary Objective:

To compare Insuman Implantable 400 IU/ml versus Insuplant 400 IU/ml with respect to the pump refill accuracy during a 4 refill cycle period (i.e. the comparative phase); To assess efficacy measured by hemoglobin glycosylated (HBA1c) change in Insuman Implantable 400 IU/ml group versus Insuplant 400 IU/ml group after a 4 refill cycle period (i.e. the comparative phase).

Secondary Objective:

To assess efficacy, safety, refill accuracy evolution and device interventions during the open-label treatment period with Insuman To evaluate daily insulin doses To assess Anti-Insulin Antibodies (ADAs or AIA) levels during all study phases

Read the detailed description

The study duration will be displayed in 2 parts as follow:

Comparative phase (only French patients): 160 +/- 20 days Open label Insuman Implantable extension phase (French and European patients): from day 160 up to the grant of Insuman implantable marketing authorization

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients already treated with Insuplant 400 IU/ml via a Medtronic Implantable System 2007
  2. Glycosylated ≤9.0%
  3. Patient showing a percentage of error at refill equal or below 20%
  4. Patient undergoing NaOH rinse procedure of at least 10 minutes period with or without flush Or Patient being re-implanted with a new pump (first fill with insulin)
  5. Signed form prior to enrolment

Exclusion criteria

Exclusion criteria:

  1. Pump life time > 6 years
  2. Pump battery voltage \< 2.6 volts
  3. Pregnancy or without a medically approved form of

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
479 participants (actual)

Study arms

  • Experimental
    Insuman Implantable

    Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.

    Drug: HUMAN INSULIN (BIOSYNTHETIC)

  • Active comparator
    Insuplant

    Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.

    Drug: Insuplant

Interventions

  • DrugHUMAN INSULIN (BIOSYNTHETIC)

    Drug pages: Insulin, Regular, Human · Insulin

    Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml

    Also known as: HR1799

  • DrugInsuplant

    Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use Dose regimen:

    Also known as: Human insulin semi synthetic porcine derived

06

What researchers measure

Primary outcomes

  1. Refill accuracy between the 2 insulin groups

    Time frame: During 4 refill cycles

  2. Change in glycosylated hemoglobin (HbA1c)

    Time frame: From baseline to 6 months

Secondary outcomes

  1. Occurrence of Hypoglycaemia (asymptomatic and symptomatic hypoglycaemia, severe and serious symptomatic hypoglycaemia

    Time frame: From baseline to 6 months

  2. Occurrence of hyperglycaemia

    Time frame: From baseline to 6 months

  3. Occurrence of diabetic ketoacidosis

    Time frame: From baseline to 6 months

  4. Change in insulin dose

    Time frame: From baseline to 6 months

  5. Antibody assessments (anti-Insulin antibodies)

    Time frame: From baseline to 6 months

07

Study locations

17 sites
  • Investigational Site Number 056-001
    Leuven, 3000, Belgium
  • Investigational Site Number 250-004
    Corbeil Essonnes, 91100, France
  • Investigational Site Number 250-008
    Dijon, 21000, France
  • Investigational Site Number 250-003
    Dommartin Les Toul, 54200, France
  • Investigational Site Number 250-012
    Le Mans Cedex 9, 72037, France
  • Investigational Site Number 250-009
    LILLE Cedex, 59037, France
  • Investigational Site Number 250-007
    Marseille, 13385, France
  • Investigational Site Number 250-001
    MONTPELLIER Cedex 5, 34295, France
  • Investigational Site Number 250-005
    Paris, 75014, France
  • Investigational Site Number 250-010
    Pessac Cedex, 33604, France
  • Investigational Site Number 250-011
    ST PRIEST EN JAREZ Cedex, 42277, France
  • Investigational Site Number 250-002
    Strasbourg, 67091, France
  • Investigational Site Number 250-006
    TOULOUSE Cedex 9, 31059, France
  • Investigational Site Number 528003
    Den Haag, 2512VA, Netherlands
  • Investigational Site Number 528002
    Roermond, 6043CV, Netherlands
  • Investigational Site Number 528001
    Zwolle, 8025AB, Netherlands
  • Investigational Site Number 752-001
    Stockholm, Sweden
08

References and documents

Publications

  • Schaepelynck P, Riveline JP, Renard E, Hanaire H, Guerci B, Baillot-Rudoni S, Sola-Gazagnes A, Catargi B, Fontaine P, Millot L, Martin JF, Tachouaft H, Jeandidier N; EVADIAC Group. Assessment of a new insulin preparation for implanted pumps used in the treatment of type 1 diabetes. Diabetes Technol Ther. 2014 Sep;16(9):582-9. doi: 10.1089/dia.2013.0369. Epub 2014 Apr 15. PubMed 24735100 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Feb 2018 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2010
First posted
Sep 3, 2010
Start
Nov 16, 2010
Primary completionActual
Feb 1, 2018
CompletionActual
Feb 1, 2018
Last update
Feb 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01194882
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 3, 2010
Start date
Nov 16, 2010
Primary completion
Feb 1, 2018
Completion
Feb 1, 2018
Last update
Feb 15, 2018

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin, Regular, Human · Insulin

Start the discussion